Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research
Pillser
Search
Sign UpLog In

Effect of vitamin K2 administration on depression status in patients with polycystic ovary syndrome: a randomized clinical trial.

  • 2022-07-26
  • BMC women's health 22(1)
    • Firoozeh Tarkesh
    • Bahia Namavar Jahromi
    • Najmeh Hejazi
    • Golazin Hoseini

Study Design

Type
Randomized Controlled Trial (RCT)
Sample size
n = 42
Population
84 PCOS women
Methods
randomized, double blind, placebo-controlled clinical trial; intervention group administered 90 µg/day Menaquinone-7, comparison group consumed placebo capsules for 8 weeks
Blinding
Double-blind
Duration
8 weeks

Background

Patients with Polycystic ovary syndrome (PCOS) are predisposed to the development of several mental comorbidities such as depression. According to several studies, PCOS can be managed by improving insulin sensitivity. The insulin-sensitizing effect of vitamin K has been reported in recent studies. Therefore, in the current trial, we assessed the effect of administrating vitamin K2 (Menaquinone-7) on depression status in women afflicted with PCOS.

Methods

Eighty-four PCOS women were allocated into the intervention and comparison groups; the intervention group (n = 42) administered 90 µg/day Menaquinone-7, and the comparison group (n = 42) consumed placebo capsules (containing avesil) for 8 weeks. In this randomized, double blind, placebo-controlled clinical trial, depression status was measured by BECK depression inventory-II (BDI-II) before and after 8 weeks of intervention.

Results

Consumption of Menaquinone-7 in comparison with the placebo capsules significantly improved depression status (P = 0.012).

Conclusion

This clinical study reported the advantageous effect of Menaquinone-7 administration on depression status in PCOS patients. Trial registration The present study was registered at http://www.IRCT.ir on 06/06/2018 (registration number: IRCT20170916036204N5).

Research Insights

  • Vitamin K2→Improved Depression Status

    Consumption of Menaquinone-7 in comparison with the placebo capsules significantly improved depression status (P = 0.012).

    Effect
    Beneficial
    Effect size
    Moderate
    Dose
    90 µg/day
Back to top